Direct Answer
Bioinformatics companies sell software and data services that analyze genomic and biological data for drug research, diagnostics and clinical labs. Revenue comes from subscriptions, per-sample analysis fees and licensed databases.
Industry Overview
Bioinformatics sits within the health care sector. The first numbers to compare across companies here are recurring revenue and retention, customer count in pharma and academia and samples or genomes analyzed. The outside forces that move them are listed under Primary Macro Drivers.
Key Industry Metrics
- Recurring revenue and retention: Subscription and database income that repeats each period, and the share of customers or dollars kept. High retention suggests the software is embedded in lab workflows; slipping retention signals churn or in-house substitutes.
- Customer count in pharma and academia: Number of paying drug-company and university customers. The split matters because academic buyers follow grant cycles while pharma buyers follow research budgets, and the two behave differently.
- Samples or genomes analyzed: Volume of biological samples or genomes processed on the platform, which drives per-sample fees. Rising throughput suggests adoption; flat volume with rising revenue means price or mix is doing the work.
- Gross margin: Share of revenue left after cloud computing, data storage and support costs of delivering analysis. Margin gains can come from scale, while a fall may reflect heavier compute costs or customized services.
- Research and development share: Percentage of revenue spent building and improving algorithms and data assets. A high share can fund product leadership but weighs on profit, so read it alongside growth and retention.
Primary Macro Drivers
- Falling sequencing costs and rising data volume: As sequencing becomes cheaper, labs generate far more data, which raises demand for analysis software and per-sample services and shows up in samples analyzed and recurring revenue.
- Pharma research and development budgets: Drugmakers fund software and data subscriptions out of research budgets, so a rise or cut in those budgets moves customer count in pharma and renewal rates.
- Public research funding: Academic and government grants pay for many licenses and analysis fees, so changes in public funding affect academic customer count and retention.
- Adoption of cloud and machine-learning tools: Cloud and machine-learning tools let customers analyze more data without building systems, which supports subscription growth and may improve gross margin as use scales.
Major Risks
- Concentration in academic funding cycles: A drop in academic grants can delay purchases and renewals at a large share of customers; watch academic customer counts and retention in recurring revenue.
- Open-source and in-house competition: Free open-source tools and customers' own software teams cap what vendors can charge; watch customer losses to in-house tools and any slowdown in net retention.
- Data privacy rules: Rules on handling genetic and patient data limit what can be stored, shared and sold, raising compliance cost and possibly narrowing licensed database revenue.
- Long enterprise sales cycles: Enterprise buyers take a long time to evaluate and sign, so revenue lags effort; watch the gap between bookings and recognized revenue and the pace of customer additions.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Mixed |
| Capital Intensity | Low |
| Regulatory Intensity | Low |
| Industry Maturity | Growth |
| Geographic Importance | U.S. / Global |
Companies Associated with Bioinformatics
The SEC's Standard Industrial Classification has no code that describes bioinformatics as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.
| Company | SEC classification | Revenue | Growth | Net margin | Year |
|---|---|---|---|---|---|
| Illumina, Inc. | Laboratory Analytical Instruments | $4.3 billion | -0.7% | 19.6% | FY 2025 |
| Simulations Plus, Inc. | Services-Computer Integrated Systems Design | $79 million | 13.1% | -81.7% | FY 2025 |
Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the company directory and the health care hub.
Where to Go Next
The Bioinformatics guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Biopharma Manufacturing Equipment
- Behavioral Health Providers
- Biosimilars
- Antibody Therapeutics
- Biotechnology
- Animal Health
- Cardiometabolic Pharmaceuticals
- Ambulatory Surgery Centers
Put it to work
Frequently Asked Questions
What are the main KPIs for the Bioinformatics industry?
Key performance indicators for the Bioinformatics industry include: Recurring revenue and retention, Customer count in pharma and academia, Samples or genomes analyzed, Gross margin, Research and development share. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Bioinformatics industry?
The Bioinformatics industry exhibits mixed cyclicality characteristics. Some segments move with the broader economy while others maintain more stable demand, making stock selection within the group particularly important.
What are the biggest risks in the Bioinformatics industry?
The primary risks for Bioinformatics companies include: Concentration in academic funding cycles, Open-source and in-house competition, Data privacy rules, Long enterprise sales cycles. Investors should assess each company's exposure to these factors and its track record of navigating them.